Clinical Trials Logo

Solid Tumor clinical trials

View clinical trials related to Solid Tumor.

Filter by:

NCT ID: NCT05497453 Not yet recruiting - Clinical trials for Hepatocellular Carcinoma

A Phase 1/2 Study to Evaluate OTX-2002 in Patients With Hepatocellular Carcinoma and Other Solid Tumor Types Known for Association With the MYC Oncogene

MYCHELANGELO I
Start date: August 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase 1/2 open-label study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of OTX-2002 as a single agent and in combination with standard of care in patients with hepatocellular carcinoma (HCC) and other solid tumor types known for association with the MYC oncogene. The study consists of Part 1 (OTX-2002 monotherapy) and Part 2 (OTX-2002 combined with standard of care in hepatocellular carcinoma). Part 1 consists of escalation and expansion, and Part 2 consists of safety run-in and expansion. The objective of Part 1 escalation and Part 2 safety run-in will be safety and tolerability, while anti-tumor activity will be evaluated as the primary endpoint in Part 1 and Part 2 expansion.

NCT ID: NCT05494762 Not yet recruiting - Solid Tumor Clinical Trials

Safety, Pharmacokinetics, and Antitumor Activity of BGB-B167 Alone and in Combination With Tislelizumab (BGB-A317) in Participants With Advanced Solid Tumors

Start date: August 2022
Phase: Phase 1
Study type: Interventional

This study will evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of BGB-B167 monotherapy and in combination with tislelizumab (BGB-A317) in participants with select advanced solid tumors.

NCT ID: NCT05490264 Not yet recruiting - Solid Tumor Clinical Trials

[68Ga]Ga-NOTA-SNA002 (PD-L1 PET Tracer) for PET/CT in Patients With Solid Tumors

Start date: August 1, 2022
Phase: Early Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety of [68Ga]Ga-NOTA-SNA002 and investigate the uptake of [68Ga]Ga-NOTA-SNA002 in patients with solid tumors.

NCT ID: NCT05485974 Not yet recruiting - Cancer Clinical Trials

A Dose Escalation Study of HBI-2438 in Patients With Solid Tumors Harboring KRAS G12C Mutation

Start date: August 2022
Phase: Phase 1
Study type: Interventional

A Phase 1 dose escalation study in patients with advanced solid tumors harboring KRAS G12C mutation to determine the maximum tolerated dose and recommended Phase II dose of HBI-2438 and characterize its pharmacokinetic profile.

NCT ID: NCT05480904 Not yet recruiting - Solid Tumor Clinical Trials

Characterizing Sleep Among Long-term Survivors of Childhood Cancer

Start date: August 2022
Phase:
Study type: Observational

The patients are being asked to take part in this clinical trial because they received cancer treatment as a child at St. Jude. The study comprehensively examines sleep among three distinct diagnostic groups of survivors in the SJLIFE cohort: ALL, CNS tumors, and non-CNS solid tumors. Primary Objective The primary aim of this protocol is to estimate the prevalence of various sleep disorders among long-term survivors of childhood ALL, CNS tumors, and non- CNS solid tumors. Exploratory Objective The exploratory objective of the study is to explore associations between the prevalence of sleep disorders and clinical outcomes collected in SJLIFE.

NCT ID: NCT05470348 Recruiting - Breast Cancer Clinical Trials

A Study of BL-B01D1 in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors

Start date: July 2022
Phase: Phase 1
Study type: Interventional

In this study, the dose-limiting toxicity (DLT), maximum tolerated dose (MTD), recommended phase II dose (RP2D), the preliminary efficacy, pharmacokinetic characteristics, and immunogenicity of BL-B01D1 will be investigated in patients with unresectable locally advanced or metastatic breast cancer and other solid tumors.

NCT ID: NCT05455866 Not yet recruiting - Solid Tumor Clinical Trials

Central Venous Catheter-related Complications in Patients Under Anticancer Treatment

KTcCHO
Start date: July 11, 2022
Phase:
Study type: Observational

Oncology and hemotology patients under anticancer treatments are exposed to increased risks of central venous catheter-related complications due to the underlying cancer and its treament. This prospective observational monocentric french study aims at describing the incidence of such complications, their morbimortality, and analyzing some risk factors in order to contribute to propose some strategies to reduce these complications' rate and consequences

NCT ID: NCT05440006 Active, not recruiting - Solid Tumor Clinical Trials

A Study of Food Effect on the Pharmacokinetics of Fuzuloparib Capsules in Chinese Healthy Adult Subjects

Start date: July 3, 2022
Phase: Phase 1
Study type: Interventional

The objective of the study is to assess the effect of food on the pharmacokinetics, and safety of Fuzuloparib Capsules in healthy subject.

NCT ID: NCT05437315 Recruiting - Solid Tumor Clinical Trials

GD2/PSMA Bi-specific CAR-T Cell Therapy

Start date: June 30, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this clinical trial is to assess the feasibility, safety and efficacy of anti-GD2/PSMA bi-specific CAR-T cell therapy in patients with GD2 and PSMA positive tumor. Another goal of the study is to learn more about the function of the anti-GD2/PSMA bi-specific CAR-T cells and their persistency in patients.

NCT ID: NCT05436093 Recruiting - Solid Tumor Clinical Trials

CLDN18.2 Targeting Nanobody Probe for PET Imaging in Solid Tumors

Start date: June 23, 2022
Phase: N/A
Study type: Interventional

The objective of the study is to construct a noninvasive approach 68Ga-ACN376 PET/CT to detect the CLDN18.2 expression of tumor lesions in patients with Solid tumors and to identify patients benefiting from CLDN18.2 targeting treatment.